Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma

Journal of Clinical Investigation

Volumn 125, Issue 11, 2015, Pages 4269-4280

  Nakashima, Hiroshi ^a   Kaufmann, Johanna K ^a,g   Wang, Pin Yi ^b   Nguyen, Tran ^a   Speranza, Maria Carmela ^a   Kasai, Kazue ^a   Okemoto, Kazuo ^c   Otsuki, Akihiro ^d   Nakano, Ichiro ^c   Fernandez, Soledad ^e   Goins, William F ^f   Grandi, Paola ^f   Glorioso, Joseph C ^f   Lawler, Sean ^a   Cripe, Timothy P ^b   Chiocca, E Antonio ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d TOTTORI UNIVERSITY   (Japan)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^g Cambridge Discovery Park   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 6; ONCOLYTIC HERPES VIRUS; ACYLTRANSFERASE; ANILIDE; BETA INTERFERON; HDAC6 PROTEIN, HUMAN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; MEC17 PROTEIN, HUMAN; MESSENGER RNA; ONCOLYTIC VIRUS; RNA; SMALL INTERFERING RNA; TUBACIN; TUBULIN; TUMOR PROTEIN; VALPROIC ACID; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL NUCLEUS; CELL SURFACE; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENDOSOME; ENZYME INHIBITION; GLIOMA; GLIOMA CELL; GLIOMA CELL LINE; GLIOMA STEM CELL; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; HUMAN TISSUE; LYSOSOME; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; TUMOR CELL; VIRUS ENTRY; VIRUS REPLICATION; ACETYLATION; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; DRUG EFFECTS; ENDOCYTOSIS; GENETICS; IN VITRO STUDY; METABOLISM; MICROTUBULE; MULTICELLULAR SPHEROID; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PROTEIN PROCESSING; PROTEIN TRANSPORT; RNA INTERFERENCE; TUMOR CELL LINE; VIROLOGY; VIRUS CAPSID;

ACETYLATION; ACETYLTRANSFERASES; ANILIDES; BRAIN NEOPLASMS; CAPSID; CELL LINE, TUMOR; CELL NUCLEUS; ENDOCYTOSIS; GLIOMA; HERPESVIRUS 1, HUMAN; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; IN VITRO TECHNIQUES; INTERFERON-BETA; LYSOSOMES; MICROTUBULES; NEOPLASM PROTEINS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; RNA INTERFERENCE; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING; RNA, VIRAL; SPHEROIDS, CELLULAR; TUBULIN; VALPROIC ACID; VIRUS REPLICATION;

EID: 84946781818     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI80713     Document Type: Article

References (66)

1. Ahluwalia MS, Chang SM. Medical therapy of gliomas. J Neurooncol. 2014;119(3):503-512.
2. Ostrom QT, et al. The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol. 2014;16(7):896-913.
3. Thomas AA, Brennan CW, DeAngelis LM, Omuro AM. Emerging therapies for glioblas-toma. JAMA Neurol. 2014;71(11):1437-1444.
4. Sturm D, et al. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer. 2014;14(2):92-107.
5. Reardon DA, et al. Immunotherapy advances for glioblastoma. Neuro Oncol. 1458;16(11):1441-1458.
6. Chiocca EA, Blair D, Mufson RA. Oncolytic viruses targeting tumor stem cells. Cancer Res. 2014;74(13):3396-3398.
7. Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res. 2014;2(4):295-300.
8. Kaufmann JK, Chiocca EA. Glioma virus therapies between bench and bedside. Neuro Oncol. 2014;16(3):334-351.
9. Chiocca EA. The host response to cancer viro-therapy. Curr Opin Mol Ther. 2008;10(1):38-45.
10. Kurozumi K, et al. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst. 2007;99(23):1768-1781.
11. Donnelly O, Harrington K, Melcher A, Pandha H. Live viruses to treat cancer. J R Soc Med. 2013;106(8):310-314.
12. Garner JA. Herpes simplex virion entry into and intracellular transport within mammalian cells. Adv Drug Deliv Rev. 2003;55(11):1497-1513.
13. Heldwein EE, Krummenacher C. Entry of herpes-viruses into mammalian cells. Cell Mol Life Sci. 2008;65(11):1653-1668.
14. Stiles KM, Krummenacher C. Glycoprotein D actively induces rapid internalization of two nec-tin-1 isoforms during herpes simplex virus entry. Virology. 2010;399(1):109-119.
15. Brencicova E, Diebold SS. Nucleic acids and endosomal pattern recognition: how to tell friend from foe? Front Cell Infect Microbiol. 2013;3:37.
16. Janke C. The tubulin code: molecular components, readout mechanisms, and functions. J Cell Biol. 2014;206(4):461-472.
17. Verhey KJ, Gaertig J. The tubulin code. Cell Cycle. 2007;6(17):2152-2160.
18. Matthias P, Yoshida M, Khochbin S. HDAC6 a new cellular stress surveillance factor. Cell Cycle. 2008;7(1):7-10.
19. Valenzuela-Fernandez A, Cabrero JR, Serrador JM, Sanchez-Madrid F. HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol. 2008;18(6):291-297.
20. Hubbert C, et al. HDAC6 is a microtubule-associated deacetylase. Nature. 2002;417(6887):455-458.
21. Gao YS, Hubbert CC, Yao TP. The microtubule-as-sociated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation. J Biol Chem. 2010;285(15):11219-11226.
22. Mak AB, et al. Regulation of CD133 by HDAC6 promotes beta-catenin signaling to suppress cancer cell differentiation. Cell Rep. 2012;2(4):951-963.
23. Kirkin V, McEwan DG, Novak I, Dikic I. A role for ubiquitin in selective autophagy. Mol Cell. 2009;34(3):259-269.
24. Nusinzon I, Horvath CM. Positive and negative regulation of the innate antiviral response and beta interferon gene expression by deacetylation. Mol Cell Biol. 2006;26(8):3106-3113.
25. Valenzuela-Fernandez A, et al. Histone deacetylase 6 regulates human immunodeficiency virus type 1 infection. Mol Biol Cell. 2005;16(11):5445-5454.
26. Kambara H, Okano H, Chiocca EA, Saeki Y. An oncolytic HSV-1 mutant expressing ICP34. Cancer Res. 2005;65(7):2832-2839.
27. Kambara H, Saeki Y, Chiocca EA. Cyclo-phosphamide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res. 2005;65(24):11255-11258.
28. Otsuki A, et al. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther. 2008;16(9):1546-1555.
29. Poon AP, Liang Y, Roizman B. Herpes simplex virus 1 gene expression is accelerated by inhibitors of his-tone deacetylases in rabbit skin cells infected with a mutant carrying a cDNA copy of the infected-cell protein no. J Virol. 2003;77(23):12671-12678.
30. Liu TC, Castelo-Branco P, Rabkin SD, Martuza RL. Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol Ther. 2008;16(6):1041-1047.
31. Nguyen TL, et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci USA. 2008;105(39):14981-14986.
32. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA. 2003;100(8):4389-4394.
33. Akella JS, et al. MEC-17 is an α-tubulin acetyl-transferase. Nature. 2010;467(7312):218-222.
34. Desai P, Person S. Incorporation of the green fluorescent protein into the herpes simplex virus type 1 capsid. J Virol. 1998;72(9):7563-7568.
35. Wang PY, et al. Expression of HSV-1 receptors in EBV-associated lymphoproliferative disease determines susceptibility to oncolytic HSV. Gene Ther. 2013;20(7):761-769.
36. Fuller AO, Spear PG. Anti-glycoprotein D antibodies that permit adsorption but block infection by herpes simplex virus 1 prevent virion-cell fusion at the cell surface. Proc Natl Acad Sci USA. 1987;84(15):5454-5458.
37. Mao P, et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci USA. 2013;110(21):8644-8649.
38. Butler KV, Kalin J, Brochier C, Vistoli G, Langley B, Kozikowski AP. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc. 2010;132(31):10842-10846.
39. White MC, Frampton AR Jr. The histone deacet-ylase inhibitor valproic acid enhances equine herpesvirus type 1 (EHV-1)-mediated oncol-ysis of human glioma cells. Cancer Gene Ther. 2013;20(2):88-93.
40. Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs. 2010;19(9):1049-1066.
41. Marks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem. 2009;107(4):600-608.
42. Cody JJ, Markert JM, Hurst DR. Histone deacet-ylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells. PLoS O ne. 2014;9(3):e92919.
43. Kim DR, et al. Combination therapy of conditionally replicating adenovirus and histone deacety-lase inhibitors. Int J Mol Med. 2012;29(2):218-224.
44. Lee JY, et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J. 2010;29(5):969-980.
45. Milne RS, Nicola AV, Whitbeck JC, Eisenberg RJ, Cohen GH. Glycoprotein D receptor-dependent, low-pH-independent endocytic entry of herpes simplex virus type 1. J Virol. 2005;79(11):6655-6663.
46. Nicola AV, Straus SE. Cellular and viral requirements for rapid endocytic entry of herpes simplex virus. J Virol. 2004;78(14):7508-7517.
47. Koyama AH, Uchida T. The mode of entry of herpes simplex virus type 1 into Vero cells. Microbiol Immunol. 1987;31(2):123-130.
48. Nicola AV, McEvoy AM, Straus SE. Roles for endocytosis and low pH in herpes simplex virus entry into HeLa and Chinese hamster ovary cells. J Virol. 2003;77(9):5324-5332.
49. Lyman MG, Enquist LW. Herpesvirus interactions with the host cytoskeleton. J Virol. 2009;83(5):2058-2066.
50. Elliott G, O'Hare P. Herpes simplex virus type 1 tegument protein VP22 induces the stabilization and hyperacetylation of microtubules. J Virol. 1998;72(8):6448-6455.
51. Yedowitz JC, Kotsakis A, Schlegel EF, Blaho JA. Nuclear localizations of the herpes simplex virus type 1 tegument proteins VP13/14, vhs, and VP16 precede VP22-dependent microtubule reorganization and VP22 nuclear import. J Virol. 2005;79(8):4730-4743.
52. Kotsakis A, Pomeranz LE, Blouin A, Blaho JA. Microtubule reorganization during herpes simplex virus type 1 infection facilitates the nuclear localization of VP22, a major virion tegument protein. J Virol. 2001;75(18):8697-8711.
53. Zilberman Y, Ballestrem C, Carramusa L, Mazitschek R, Khochbin S, Bershadsky A. Regulation of microtubule dynamics by inhibition of the tubulin deacetylase HDAC6. J Cell Sci. 2009;122(pt 19):3531-3541.
54. Kovacs JJ, Hubbert C, Yao TP. The HDAC complex and cytoskeleton. Novartis Found Symp. 2004;259:170-177.
55. Nakashima H, Nguyen T, Goins WF, Chiocca EA. Interferon-stimulated gene 15 (ISG15) and ISG15-linked proteins can associate with members of the selective autophagic process, histone deacetylase 6 (HDAC6) and SQSTM1/p62. J Biol Chem. 2015;290(3):1485-1495.
56. Banerjee I, et al. Influenza A virus uses the aggre-some processing machinery for host cell entry. Science. 2014;346(6208):473-477.
57. Abaitua F, Hollinshead M, Bolstad M, Crump CM, O'Hare P. A Nuclear localization signal in herpesvirus protein VP1-2 is essential for infection via capsid routing to the nuclear pore. J Virol. 2012;86(17):8998-9014.
58. Jovasevic V, Liang L, Roizman B. Proteolytic cleavage of VP1-2 is required for release of herpes simplex virus 1 DNA into the nucleus. J Virol. 2008;82(7):3311-3319.
59. Husain M, Cheung CY. Histone deacetylase 6 inhibits influenza A virus release by downregu-lating the trafficking of viral components to the plasma membrane via its substrate, acetylated microtubules. J Virol. 2014;88(19):11229-11239.
60. Vaughan EE, et al. Microtubule acetyla-tion through HDAC6 inhibition results in increased transfection efficiency. Mol Ther. 2008;16(11):1841-1847.
61. Barua S, Rege K. The influence of mediators of intracellular trafficking on transgene expression efficacy of polymer-plasmid DNA complexes. Biomaterials. 2010;31(22):5894-5902.
62. Peruzzi P, et al. MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells. Neuro Oncol. 2013;15(9):1212-1224.
63. Krisky DM, et al. Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther. 1998;5(12):1593-1603.
64. Uchida H, et al. Effective treatment of an ortho-topic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol Ther. 2013;21(3):561-569.
65. Goins WF, Huang S, Cohen JB, Glorioso JC. Engineering HSV-1 vectors for gene therapy. Methods Mol Biol. 2014;1144:63-79.
66. Saeki Y, Fraefel C, Ichikawa T, Breakefield XO, Chiocca EA. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther. 2001;3(4):591-601.